Market opportunities for glioblastoma treatment
Glioblastoma (GBM) represents the most frequent malignant brain tumor in adults with an annual incidence of 3.21 per 100,000 persons.
In 2022 there were 321,000 worldwide diagnosed incident cases of brain and central nervous system cancer. 50 % of brain and CNS cancer are glioblastoma.
A recent study evaluated the GBM market size at 2.78 USD billion in 2024 and it is expected to reach around USD 5.68 billion by 2033, registering a CAGR (compound annual growth rate) of 8.23% from 2024 to 2033. GBM patients currently have no curative treatment options and a low survival expectancy, thus, there is the potential for high uptake of any therapy able to improve survival or quality of life.
GBM market in the 8MM
$5.68 B in
2033
23,000
patients/year diagnosed with brain cancer in Europe
16,000
patients/year diagnosed with brain cancer in the USA
Today, there is an overall lack of approved therapies for GBM patients, with only two drugs specifically approved: temozolomide and bevacizumab. These chemotherapies are adjuvant only, delivered 6 weeks after surgery. The cornerstone of the management remains surgery and our solution has thus been designed to be seamlessly delivered during the surgery performed upfront. Our cross-labelled products comply with framework of drug-device combination products from the FDA and EMA.
- More than 50% of brain cancers are GBM
- Median overall survival remains lower than 16 months for patients harboring GBM
- Standard of Care has not been improved since 2005
Prescribers
Hemerion’s strategy aims to market its technology to the neurosurgeons located in Europe and USA:
6,800
board-certified neurosurgeons in Europe
3,800
board-certified neurosurgeons in the USA
25,000 patients are eligible per year to our therapeutic approach. We estimate that 65% of brain cancer surgeries could be achieved with Hemerion’s technology within the 5 years post market authorization (around 2034).
Capital and funding
The company is currently funded via founders, public subsidies, loans and several venture capital players.
Our team is actively seeking new financial partners to speed up and widen its clinical and innovation programs.